Effect of Sodium Glucose Co-transporter Type 2 Inhibitors on The Infract size among Diabetic Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | ||||
| Zagazig University Medical Journal | ||||
| Volume 30, Issue 1.3, March and April 2024, Page 336-346 PDF (625.78 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/zumj.2024.275740.3237 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Moataz A. Elkot  1; Yasser Gaber Metwally2; Refaat Mohamed Refaat3; Hala Gouda Abomandour4
| ||||
| 1Lecturer of cardiology faculty of medicine zagazig university | ||||
| 2The Department of Cardiology, faculty of medicine ,Zagazig University, Zagazig, Egypt. | ||||
| 3Cardiology department al-ahrar teaching hospital | ||||
| 4A. professor of cardiology department faculty of medicine zagazig university | ||||
| Abstract | ||||
| Background: Myocardial ischemia causes cell death, which sets off an inflammatory cascade that eventually leads to the formation of scars.Sodium-glucose co-transporter-2 inhibitors(SGLT2I) used in the management of patients with type 2 diabetes. Aim: Is to evaluate the long-term treatment with SGLT2I on decreasing the infarct size in STEMI diabetic patientswho undergoing primary percutaneous coronary intervention. methods: This Comparative study included 30 patients who were admitted with STEMI undergoing Primary PCI. Patients were divided equally into group(1) : diabetic patients not on SGLT2I & group 2 :diabetic patients on SGLT2I for more than 6 months. Baseline characteristics, echocardiographic parameters , angiographic and procedural data, medication use, and outcome data were recorded prospectively. Results: Regarding biomarkers, hs-TnI levels were significantly higher in non SGLT2I group compared to SGLT2I group (P<0.05).Furthermore, the angiography finding, TIMI flow after PCI was significantly improved in SGLT2I group compared to non SGLT2I group P=0.029. On hospital discharge, ST resolution and Ejection Fraction(EF) were significantly higher in SGLT2I group compared to non SGLT2I group P<0.001 ,also WMSI on hospital discharge was significantly higher in non SGLT2I group compared to SGLT2I group P=0.007 . Mitral regurgitation was significantly different between both groups, being significantly improved in SGLT2I group compared to non SGLT2I group P=0.003. Baseline EF, WMSI and mitral regurgitation were insignificantly different between both groups. Conclusion: Diabetic patients with STEMI undergoing PPCI and treated with SGLT2I exhibited significantly decreased the infract size and improved cardiovascular outcomes compared to those not on SGLT2Itherapy. | ||||
| Keywords | ||||
| Infarction size; post PCI TIMI flow; wall motion Score Index | ||||
|
Statistics Article View: 151 PDF Download: 95 |
||||
